Liver-Targeted Drug Delivery Using HepDirect1 Prodrugs

@article{Erion2005LiverTargetedDD,
  title={Liver-Targeted Drug Delivery Using HepDirect1 Prodrugs},
  author={Mark D. Erion and Paul D. van Poelje and Deidre A Mackenna and Timothy J. Colby and Annika C. Montag and James M. Fujitaki and David L. Linemeyer and David A. Bullough},
  journal={Journal of Pharmacology and Experimental Therapeutics},
  year={2005},
  volume={312},
  pages={554 - 560}
}
Targeting drugs to specific organs, tissues, or cells is an attractive strategy for enhancing drug efficacy and reducing side effects. Drug carriers such as antibodies, natural and manmade polymers, and labeled liposomes are capable of targeting drugs to blood vessels of individual tissues but often fail to deliver drugs to extravascular sites. An alternative strategy is to use low molecular weight prodrugs that distribute throughout the body but cleave intracellularly to the active drug by an… 
Design and Evaluation of Nucleoside Derivatives for Targeted Drug Delivery and Therapeutic Applications
TLDR
The conjugates are able to deliver 1 to 3 nucleoside analogs to the HIVinfected cells and may result in development of anti-HIV agents having enhanced lipophilicity, longer duration of action by sustained intracellular release of active substrates at adequate concentrations, higher uptake into infected cells, and/or site specificity.
LIVER TARGETING OF HEPATITIS-B ANTIVIRAL LAMIVUDINE USING THE HEPDIRECT™ PRODRUG TECHNOLOGY
TLDR
A new class of phosphate and phosphonate prodrugs, called HepDirect™ prodrugS, has been developed to deliver drugs to the liver while simultaneously diminishing drug exposure to extra-hepatic tissues, and generated 34-fold higher levels of the triphosphate in rat hepatocytes and 320-fold lower levels in the liver of treated rats relative to LMV.
Prodrugs for Liver-targeted Drug Delivery
TLDR
This chapter reviews the liver-targeting strategies explored to date and, more specifically, the strengths and weaknesses of various prodrug strategies used for liver-specific drug delivery.
Prodrugs and Drug Delivery Systems
This chapter discusses enzyme activation of drugs, mechanisms of drug activation, and bioprecursor prodrugs. The term “prodrug” is a pharmacologically inactive compound that is converted into an
Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting.
TLDR
This review presents advances of prodrug approaches for improved oral absorption of nucleoside analogues and recent developments in tissue targeting.
Novel Prodrug Structures for Improved Drug Delivery
The requirements demanded with respect to the potency and safety of novel chemical entities are increasing and correspondingly the financial investments needed for developing a new drug are
Discovery of an Orally Active and Liver-Targeted Prodrug of 5-Fluoro-2'-Deoxyuridine for the Treatment of Hepatocellular Carcinoma.
TLDR
A series of novel O-(substituted benzyl) phosphoramidate prodrugs of 5-fluoro-2'-deoxyuridine for the treatment of hepatocellular carcinoma are reported, with the o-methylbenzyl analog (1t) identified as an orally bioavailable and liver-targeted lead compound.
Delivery of high levels of anti-proliferative nucleoside triphosphates to CYP3A-expressing cells as a potential treatment for hepatocellular carcinoma
TLDR
As the levels of araCTP achieved in the liver at therapeutic doses are only toxic to proliferating cells, but not the non-proliferative adjacent tissue, MB07133 treatment has the potential to be both efficacious and well tolerated in HCC patients.
EMULSOMES: AN EMERGING VESICULAR DRUG DELIVERY SYSTEM
TLDR
The concept of emulsomal drug delivery system is addressed, special attention has been paid to its formulation design, advantages, biopharmaceutical aspects, stability aspects, and various aspects related to drug delivery including future aspects.
Polymeric nanogels containing the triphosphate form of cytotoxic nucleoside analogues show antitumor activity against breast and colorectal cancer cell lines
TLDR
Active triphosphates of NA encapsulated in nanogels exhibit similar cytotoxicity and cell cycle perturbations in vitro and faster cell accumulation and equal tumor growth-inhibitory activity in vivo at much lower dose compared with parental drugs, illustrating their therapeutic potential for cancer chemotherapy.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 48 REFERENCES
Targeting hepatocytes for drug and gene delivery: emerging novel approaches and applications.
The asialoglycoprotein receptor (ASGP-R) on mammalian hepatocytes provides a unique means for the development of liver-specific carriers, such as liposomes, recombinant lipoproteins, and polymers for
Liver-specific drug targeting by coupling to bile acids.
TLDR
Modified bile acid molecules can be used as "Trojan horses" to deliver a drug molecule specifically into the liver and the biliary system and offers important pharmacological options for the development of liver-specific drugs.
Design, synthesis, and characterization of a series of cytochrome P(450) 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver.
TLDR
The ability of a new class of phosphate and phosphonate prodrugs to effectively bypass the rate-limiting nucleoside kinase step and produce higher levels of the biologically active nucleosid triphosphate is demonstrated.
Theory and practice of site-specific drug delivery
TLDR
The rationale for site-specific drug delivery in terms of disease and drug and carrier properties is examined, and the biological constraints and opportunities are examined by considering carrier access, retention and ability to control the timing of drug availability at site(s of action(s).
Antibody directed enzymes revive anti-cancer prodrugs concept.
TLDR
Within a few years of the beginnings of cancer chemotherapy anticancer prodrugs were being synthesised, one of the compounds produced at the Chester Beatty had a profound effect on growth of the Walker rat carcinoma, both in vivo and in culture, whilst it had little or no effect on other cancers.
Nanocrystal targeting in vivo
TLDR
Qdots are small (<10 nm) inorganic nanocrystals that possess unique luminescent properties; their fluorescence emission is stable and tuned by varying the particle size or composition, and these results encourage the construction of more complex nanostructures with capabilities such as disease sensing and drug delivery.
Drug uptake systems in liver and kidney.
TLDR
The tissue distribution, substrate specificity, transport mechanism, and regulation of the members of the organic anion transporting polypeptide (Oatp/OATP) superfamily (solute carrier family SLC21A) and the SLC22A family containing transporters for organic cations (OCTs) and organic anions (OATs) are discussed.
The potential impact of drug transporters on nucleoside-analog-based antiviral chemotherapy.
TLDR
How ABC transporters in general, and MRPs in particular, could affect the disposition and cellular accumulation of antiviral compounds is reviewed.
Site-specific, sustained release of drugs to the brain.
A dihydropyridine-pyridinium salt type of redox system is used in a general and flexible method for the site-specific or sustained delivery (or both) of drugs to the brain. A biologically active
Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model.
TLDR
In vivo selection of phage display libraries was used to isolate peptides that home specifically to tumor blood vessels that enhanced the efficacy of the anticancer drug doxorubicin and reduced its toxicity.
...
1
2
3
4
5
...